Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 72 entries
Sorted by: Best Match Show Resources per page
Use of Digital Pupillometry to Measure Sedative Response to Propofol.

The Ochsner journal

Haddock JH, Mercante DE, Paccione R, Breaux JL, Jolley SE, Johnson JL, Connolly SE, deBoisblanc BP.
PMID: 29026357
Ochsner J. 2017;17(3):250-253.

BACKGROUND: Digital pupillometry (DP) accurately and precisely measures pupillary responses. Little is known about using DP to measure the sedative effect of isolated propofol administration.METHODS: We conducted a cross-sectional study of 19 adults undergoing moderate sedation with propofol during...

Cite
Haddock JH, Mercante DE, Paccione R, et al. Use of Digital Pupillometry to Measure Sedative Response to Propofol. Ochsner J. 2017;17(3):250-253
Haddock, J. H., Mercante, D. E., Paccione, R., Breaux, J. L., Jolley, S. E., Johnson, J. L., Connolly, S. E., & deBoisblanc, B. P. (2017). Use of Digital Pupillometry to Measure Sedative Response to Propofol. The Ochsner journal, 17(3), 250-253.
Haddock, Jody H, et al. "Use of Digital Pupillometry to Measure Sedative Response to Propofol." The Ochsner journal vol. 17,3 (2017): 250-253.
Haddock JH, Mercante DE, Paccione R, Breaux JL, Jolley SE, Johnson JL, Connolly SE, deBoisblanc BP. Use of Digital Pupillometry to Measure Sedative Response to Propofol. Ochsner J. 2017;17(3):250-253. PMID: 29026357; PMCID: PMC5625983.
Copy Download .nbib Format: NLM
Preadmission Predictors of On-time Graduation in a Doctor of Pharmacy Program.

American journal of pharmaceutical education

Allen RE, Diaz C, Gant K, Taylor A, Onor I.
PMID: 27170814
Am J Pharm Educ. 2016 Apr 25;80(3):43. doi: 10.5688/ajpe80343.

Objective. To determine which preadmission variables or combination of variables are able to predict on-time graduation in a doctor of pharmacy program. Methods. Transcripts and student files were reviewed for 460 students who entered the college between 2007 and...

Cite
Allen RE, Diaz C, Gant K, et al. Preadmission Predictors of On-time Graduation in a Doctor of Pharmacy Program. Am J Pharm Educ. 2016;80(3):43doi: 10.5688/ajpe80343.
Allen, R. E., Diaz, C., Gant, K., Taylor, A., & Onor, I. (2016). Preadmission Predictors of On-time Graduation in a Doctor of Pharmacy Program. American journal of pharmaceutical education, 80(3), 43. https://doi.org/10.5688/ajpe80343
Allen, Rondall E, et al. "Preadmission Predictors of On-time Graduation in a Doctor of Pharmacy Program." American journal of pharmaceutical education vol. 80,3 (2016): 43. doi: https://doi.org/10.5688/ajpe80343
Allen RE, Diaz C, Gant K, Taylor A, Onor I. Preadmission Predictors of On-time Graduation in a Doctor of Pharmacy Program. Am J Pharm Educ. 2016 Apr 25;80(3):43. doi: 10.5688/ajpe80343. PMID: 27170814; PMCID: PMC4857638.
Copy Download .nbib Format: NLM
Synthesis of 5-Substituted Derivatives of Isophthalic Acid as Non-Polymeric Amphiphilic Coating for Metal Oxide Nanoparticles.

Tetrahedron letters

Nilov D, Kucheryavy P, Walker V, Kidd C, Kolesnichenko VL, Goloverda GZ.
PMID: 25152545
Tetrahedron Lett. 2014 Sep 03;55(36):5078-5081. doi: 10.1016/j.tetlet.2014.07.061.

In the course of development of novel capping ligands with variable steric factor, which will be used as an organic coating for metal oxide nanoparticles, a base-catalyzed nucleophilic oxirane ring-opening addition reaction between dimethyl 5-hydroxyisophthalate and allyl glycidyl ether...

Cite
Nilov D, Kucheryavy P, Walker V, et al. Synthesis of 5-Substituted Derivatives of Isophthalic Acid as Non-Polymeric Amphiphilic Coating for Metal Oxide Nanoparticles. Tetrahedron Lett. 2014;55(36):5078-5081doi: 10.1016/j.tetlet.2014.07.061.
Nilov, D., Kucheryavy, P., Walker, V., Kidd, C., Kolesnichenko, V. L., & Goloverda, G. Z. (2014). Synthesis of 5-Substituted Derivatives of Isophthalic Acid as Non-Polymeric Amphiphilic Coating for Metal Oxide Nanoparticles. Tetrahedron letters, 55(36), 5078-5081. https://doi.org/10.1016/j.tetlet.2014.07.061
Nilov, Denis, et al. "Synthesis of 5-Substituted Derivatives of Isophthalic Acid as Non-Polymeric Amphiphilic Coating for Metal Oxide Nanoparticles." Tetrahedron letters vol. 55,36 (2014): 5078-5081. doi: https://doi.org/10.1016/j.tetlet.2014.07.061
Nilov D, Kucheryavy P, Walker V, Kidd C, Kolesnichenko VL, Goloverda GZ. Synthesis of 5-Substituted Derivatives of Isophthalic Acid as Non-Polymeric Amphiphilic Coating for Metal Oxide Nanoparticles. Tetrahedron Lett. 2014 Sep 03;55(36):5078-5081. doi: 10.1016/j.tetlet.2014.07.061. PMID: 25152545; PMCID: PMC4138530.
Copy Download .nbib Format: NLM
Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD).

Oncotarget

Zhang C, Guo S, Yang L, Liu J, Zheng S, Zhong Q, Zhang Q, Wang G.
PMID: 29262607
Oncotarget. 2017 Oct 10;8(61):103874-103889. doi: 10.18632/oncotarget.21808. eCollection 2017 Nov 28.

ZB716 is a selective estrogen receptor downregulator (SERD) with excellent oral bioavailability and superior efficacy. In this study, we investigate the

Cite
Zhang C, Guo S, Yang L, et al. Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget. 2017;8(61):103874-103889doi: 10.18632/oncotarget.21808.
Zhang, C., Guo, S., Yang, L., Liu, J., Zheng, S., Zhong, Q., Zhang, Q., & Wang, G. (2017). Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget, 8(61), 103874-103889. https://doi.org/10.18632/oncotarget.21808
Zhang, Changde, et al. "Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD)." Oncotarget vol. 8,61 (2017): 103874-103889. doi: https://doi.org/10.18632/oncotarget.21808
Zhang C, Guo S, Yang L, Liu J, Zheng S, Zhong Q, Zhang Q, Wang G. Metabolism, pharmacokinetics, and bioavailability of ZB716, a Steroidal Selective Estrogen Receptor Downregulator (SERD). Oncotarget. 2017 Oct 10;8(61):103874-103889. doi: 10.18632/oncotarget.21808. eCollection 2017 Nov 28. PMID: 29262607; PMCID: PMC5732773.
Copy Download .nbib Format: NLM
OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315.

Journal of undergraduate chemistry research

Foroozesh M, Goyal N, Jackson T, Do C, Booker S, Hill T, Liu J.
PMID: 30220887
J Undergrad Chem Res. 2017;16(3):89-90.

Ceramides, serve as central mediators in sphingolipid metabolism and signaling pathways. They function in signaling events which induce apoptosis, cell cycle arrest, and autophagic responses. In cancer cells, ceramide levels are often suppressed by the up-regulation of ceramide-metabolizing enzymes...

Cite
Foroozesh M, Goyal N, Jackson T, et al. OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315. J Undergrad Chem Res. 2017;16(3):89-90
Foroozesh, M., Goyal, N., Jackson, T., Do, C., Booker, S., Hill, T., & Liu, J. (2017). OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315. Journal of undergraduate chemistry research, 16(3), 89-90.
Foroozesh, Maryam, et al. "OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315." Journal of undergraduate chemistry research vol. 16,3 (2017): 89-90.
Foroozesh M, Goyal N, Jackson T, Do C, Booker S, Hill T, Liu J. OPTIMIZATION OF SCALE-UP SYNTHESIS OF ANTI-CANCER CERAMIDE ANALOG 315. J Undergrad Chem Res. 2017;16(3):89-90. PMID: 30220887; PMCID: PMC6138050.
Copy Download .nbib Format: NLM
Ultra-thin iron phosphate nanosheets for high efficient U(VI) adsorption.

Journal of hazardous materials

Wang, Xu Y, Xiao D, Qiao Q, Yin P, Yang Z, Li J, Winchester W, Wang Z, Hayat T.
PMID: 30849574
J Hazard Mater. 2019 Jun 05;371:83-93. doi: 10.1016/j.jhazmat.2019.02.091. Epub 2019 Feb 25.

In this study, the ultra-thin iron phosphate Fe

Cite
Wang, Xu Y, Xiao D, et al. Ultra-thin iron phosphate nanosheets for high efficient U(VI) adsorption. J Hazard Mater. 2019;371:83-93doi: 10.1016/j.jhazmat.2019.02.091.
Wang, Xu, Y., Xiao, D., Qiao, Q., Yin, P., Yang, Z., Li, J., Winchester, W., Wang, Z., & Hayat, T. (2019). Ultra-thin iron phosphate nanosheets for high efficient U(VI) adsorption. Journal of hazardous materials, 37183-93. https://doi.org/10.1016/j.jhazmat.2019.02.091
Wang, De, et al. "Ultra-thin iron phosphate nanosheets for high efficient U(VI) adsorption." Journal of hazardous materials vol. 371 (2019): 83-93. doi: https://doi.org/10.1016/j.jhazmat.2019.02.091
Wang, Xu Y, Xiao D, Qiao Q, Yin P, Yang Z, Li J, Winchester W, Wang Z, Hayat T. Ultra-thin iron phosphate nanosheets for high efficient U(VI) adsorption. J Hazard Mater. 2019 Jun 05;371:83-93. doi: 10.1016/j.jhazmat.2019.02.091. Epub 2019 Feb 25. PMID: 30849574; PMCID: PMC6759232.
Copy Download .nbib Format: NLM
Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines.

ACS omega

Schroeder R, Sfondouris M, Goyal N, Komati R, Weerathunga A, Gettridge C, Stevens CLK, Jones FE, Sridhar J.
PMID: 31460159
ACS Omega. 2019 Jun 19;4(6):10610-10619. doi: 10.1021/acsomega.9b00929. eCollection 2019 Jun 30.

Human epidermal growth factor receptor 2 (HER2) is overexpressed in nearly 20-30% of breast cancers and is associated with metastasis resulting in poor patient survival and high recurrence. The dual EGFR/HER2 kinase inhibitor lapatinib has shown promising clinical results,...

Cite
Schroeder R, Sfondouris M, Goyal N, et al. Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. ACS Omega. 2019;4(6):10610-10619doi: 10.1021/acsomega.9b00929.
Schroeder, R., Sfondouris, M., Goyal, N., Komati, R., Weerathunga, A., Gettridge, C., Stevens, C. L. K., Jones, F. E., & Sridhar, J. (2019). Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. ACS omega, 4(6), 10610-10619. https://doi.org/10.1021/acsomega.9b00929
Schroeder, Richard, et al. "Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines." ACS omega vol. 4,6 (2019): 10610-10619. doi: https://doi.org/10.1021/acsomega.9b00929
Schroeder R, Sfondouris M, Goyal N, Komati R, Weerathunga A, Gettridge C, Stevens CLK, Jones FE, Sridhar J. Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines. ACS Omega. 2019 Jun 19;4(6):10610-10619. doi: 10.1021/acsomega.9b00929. eCollection 2019 Jun 30. PMID: 31460159; PMCID: PMC6648266.
Copy Download .nbib Format: NLM
Ultrathin layered double hydroxide nanosheets with Ni(III) active species obtained by exfoliation for highly efficient ethanol electrooxidation.

Electrochimica acta

Xu L, Wang Z, Chen X, Qu Z, Li F, Yang W.
PMID: 29622818
Electrochim Acta. 2018 Jan 10;260:898-904. doi: 10.1016/j.electacta.2017.12.065. Epub 2017 Dec 12.

The development of non-precious metal electrocatalysts for renewable energy conversion and storage is compelling but greatly challenging due to low activity of the existing catalysts. Herein, the ultrathin NiAl-layered double hydroxide nanosheets (NiAl-LDH-NSs) are prepared by simple liquid-exfoliation of...

Cite
Xu L, Wang Z, Chen X, et al. Ultrathin layered double hydroxide nanosheets with Ni(III) active species obtained by exfoliation for highly efficient ethanol electrooxidation. Electrochim Acta. 2017;260:898-904doi: 10.1016/j.electacta.2017.12.065.
Xu, L., Wang, Z., Chen, X., Qu, Z., Li, F., & Yang, W. (2018). Ultrathin layered double hydroxide nanosheets with Ni(III) active species obtained by exfoliation for highly efficient ethanol electrooxidation. Electrochimica acta, 260898-904. https://doi.org/10.1016/j.electacta.2017.12.065
Xu, Liang, et al. "Ultrathin layered double hydroxide nanosheets with Ni(III) active species obtained by exfoliation for highly efficient ethanol electrooxidation." Electrochimica acta vol. 260 (2018): 898-904. doi: https://doi.org/10.1016/j.electacta.2017.12.065
Xu L, Wang Z, Chen X, Qu Z, Li F, Yang W. Ultrathin layered double hydroxide nanosheets with Ni(III) active species obtained by exfoliation for highly efficient ethanol electrooxidation. Electrochim Acta. 2018 Jan 10;260:898-904. doi: 10.1016/j.electacta.2017.12.065. Epub 2017 Dec 12. PMID: 29622818; PMCID: PMC5881604.
Copy Download .nbib Format: NLM
The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate.

Acta crystallographica. Section E, Structure reports online

Payton-Stewart F, Ravi Kiran Pingali S, Donahue JP.
PMID: 23634097
Acta Crystallogr Sect E Struct Rep Online. 2013 Mar 23;69:o558-9. doi: 10.1107/S160053681300696X. Print 2013 Apr 01.

The title compound, C16H13FO3·H2O, has a cis disposition of the carbonyl and olefin bonds about the enone single bond. The arene rings are inclined to one another by 10.05 (6) Å. In the crystal, mol-ecules are linked via O-H⋯O...

Cite
Payton-Stewart F, Ravi Kiran Pingali S, Donahue JP. The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate. Acta Crystallogr Sect E Struct Rep Online. 2013;69:o558-9doi: 10.1107/S160053681300696X.
Payton-Stewart, F., Ravi Kiran Pingali, S., & Donahue, J. P. (2013). The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate. Acta crystallographica. Section E, Structure reports online, 69o558-9. https://doi.org/10.1107/S160053681300696X
Payton-Stewart, Florastina, et al. "The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate." Acta crystallographica. Section E, Structure reports online vol. 69 (2013): o558-9. doi: https://doi.org/10.1107/S160053681300696X
Payton-Stewart F, Ravi Kiran Pingali S, Donahue JP. The chalcone derivative (E)-1-(4-fluoro-phen-yl)-3-(4-hy-droxy-3-meth-oxy-phen-yl)prop-2-en-1-one monohydrate. Acta Crystallogr Sect E Struct Rep Online. 2013 Mar 23;69:o558-9. doi: 10.1107/S160053681300696X. Print 2013 Apr 01. PMID: 23634097; PMCID: PMC3629610.
Copy Download .nbib Format: NLM
AACP Special Taskforce White Paper on Diversifying Our Investment in Human Capital.

American journal of pharmaceutical education

White C, Conway JM, Davis PK, Johnson-Fannin AM, Jurkas JG, Murphy NL, Smith WT, Echeverri M, Youmans SL, Owings KC, Adams JL.
PMID: 29200461
Am J Pharm Educ. 2017 Oct;81(8):S13. doi: 10.5688/ajpeS13.

The 2015-2017 American Association of Colleges of Pharmacy (AACP) Special Taskforce on Diversifying our Investment in Human Capital was appointed for a two-year term, due to the rigors and complexities of its charges. This report serves as a white...

Cite
White C, Conway JM, Davis PK, et al. AACP Special Taskforce White Paper on Diversifying Our Investment in Human Capital. Am J Pharm Educ. 2017;81(8):S13doi: 10.5688/ajpeS13.
White, C., Conway, J. M., Davis, P. K., Johnson-Fannin, A. M., Jurkas, J. G., Murphy, N. L., Smith, W. T., Echeverri, M., Youmans, S. L., Owings, K. C., & Adams, J. L. (2017). AACP Special Taskforce White Paper on Diversifying Our Investment in Human Capital. American journal of pharmaceutical education, 81(8), S13. https://doi.org/10.5688/ajpeS13
White, Carla, et al. "AACP Special Taskforce White Paper on Diversifying Our Investment in Human Capital." American journal of pharmaceutical education vol. 81,8 (2017): S13. doi: https://doi.org/10.5688/ajpeS13
White C, Conway JM, Davis PK, Johnson-Fannin AM, Jurkas JG, Murphy NL, Smith WT, Echeverri M, Youmans SL, Owings KC, Adams JL. AACP Special Taskforce White Paper on Diversifying Our Investment in Human Capital. Am J Pharm Educ. 2017 Oct;81(8):S13. doi: 10.5688/ajpeS13. PMID: 29200461; PMCID: PMC5701336.
Copy Download .nbib Format: NLM
Genetic alterations of interleukin-17 and related genes in human prostate cancer.

American journal of clinical and experimental urology

Lan R, Zhang K, Niu T, You Z.
PMID: 31970232
Am J Clin Exp Urol. 2019 Dec 15;7(6):352-377. eCollection 2019.

Interleukin-17 (

Cite
Lan R, Zhang K, Niu T, et al. Genetic alterations of interleukin-17 and related genes in human prostate cancer. Am J Clin Exp Urol. 2019;7(6):352-377
Lan, R., Zhang, K., Niu, T., & You, Z. (2019). Genetic alterations of interleukin-17 and related genes in human prostate cancer. American journal of clinical and experimental urology, 7(6), 352-377.
Lan, Ruoxin, et al. "Genetic alterations of interleukin-17 and related genes in human prostate cancer." American journal of clinical and experimental urology vol. 7,6 (2019): 352-377.
Lan R, Zhang K, Niu T, You Z. Genetic alterations of interleukin-17 and related genes in human prostate cancer. Am J Clin Exp Urol. 2019 Dec 15;7(6):352-377. eCollection 2019. PMID: 31970232; PMCID: PMC6971475.
Copy Download .nbib Format: NLM
Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents.

Translational cancer research

Wang G.
PMID: 32968620
Transl Cancer Res. 2020 Aug;9(8):4464-4468. doi: 10.21037/tcr-20-2166.

No abstract available.

Cite
Wang G. Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents. Transl Cancer Res. 2020;9(8):4464-4468doi: 10.21037/tcr-20-2166.
Wang, G. (2020). Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents. Translational cancer research, 9(8), 4464-4468. https://doi.org/10.21037/tcr-20-2166
Wang, Guangdi. "Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents." Translational cancer research vol. 9,8 (2020): 4464-4468. doi: https://doi.org/10.21037/tcr-20-2166
Wang G. Fulvestrant as a reference antiestrogen and estrogen receptor (ER) degrader in preclinical studies: treatment dosage, efficacy, and implications on development of new ER-targeting agents. Transl Cancer Res. 2020 Aug;9(8):4464-4468. doi: 10.21037/tcr-20-2166. PMID: 32968620; PMCID: PMC7508469.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 72 entries